uniQure N.V. (NASDAQ: QURE) stock fell -3.52% on Monday to $21.12 against a previous-day closing price of $21.89. With 0.53 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.7 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $21.87 whereas the lowest price it dropped to was $21.05. The 52-week range on QURE shows that it touched its highest point at $28.25 and its lowest point at $12.52 during that stretch. It currently has a 1-year price target of $52.00. Beta for the stock currently stands at 1.11.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QURE was down-trending over the past week, with a drop of -8.45%, but this was down by -8.29% over a month. Three-month performance surged to 13.43% while six-month performance fell -14.11%. The stock gained 15.66% in the past year, while it has lost -6.84% so far this year. A look at the trailing 12-month EPS for QURE yields -2.69 with Next year EPS estimates of -1.17. For the next quarter, that number is -0.89. This implies an EPS growth rate of 350.30% for this year and 68.80% for next year.
Float and Shares Shorts:
At present, 46.77 million QURE shares are outstanding with a float of 43.44 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.0 million, which was 6.42% higher than short shares on Sep 14, 2022. In addition to Mr. Matthew Craig Kapusta as the firm’s CEO & Exec. Director, Mr. Christian Klemt serves as its CFO, Principal Financial Officer & GM of Amsterdam Site.
Through their ownership of 91.34% of QURE’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 45.92% of QURE, in contrast to 42.59% held by mutual funds. Shares owned by individuals account for 12.40%. As the largest shareholder in QURE with 9.79% of the stake, BlackRock Fund Advisors holds 4,584,495 shares worth 4,584,495. A second-largest stockholder of QURE, Point72 Asset Management LP, holds 4,259,886 shares, controlling over 9.10% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in QURE, holding 3,063,265 shares or 6.54% stake. With a 6.50% stake in QURE, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 3,042,277 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 4.14% of QURE stock, is the second-largest Mutual Fund holder. It holds 1,938,014 shares valued at 43.93 million. Worldwide Healthcare Trust Plc holds 2.41% of the stake in QURE, owning 1,128,379 shares worth 25.58 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for QURE since 19 analysts follow the stock currently. There are 17 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With QURE analysts setting a high price target of $90.00 and a low target of $24.00, the average target price over the next 12 months is $52.35. Based on these targets, QURE could surge 326.14% to reach the target high and rise by 13.64% to reach the target low. Reaching the average price target will result in a growth of 147.87% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. QURE will report FY 2022 earnings on 02/23/2024. Analysts have provided yearly estimates in a range of -$2.00 being high and -$4.46 being low. For QURE, this leads to a yearly average estimate of -$3.75. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. uniQure N.V. surprised analysts by $0.18 when it reported -$1.02 EPS against a consensus estimate of -$1.20. The surprise factor in the prior quarter was $0.16. Based on analyst estimates, the high estimate for the next quarter is $0.86 and the low estimate is -$1.60. The average estimate for the next quarter is thus -$0.89.
Summary of Insider Activity:
Insiders traded QURE stock several times over the past three months with 8 Buys and 8 Sells. In these transactions, 52,375 shares were bought while 29,754 shares were sold. The number of buy transactions has increased to 33 while that of sell transactions has risen to 31 over the past year. The total number of shares bought during that period was 476,663 while 130,037 shares were sold.